KV-002

KV-002 is an oxepanoprolinamide (OPP) antibiotic being developed by Kinvard Bio, a biotechnology company spun out from Harvard University's Myers Lab. This small molecule antibiotic targets the bacterial ribosome's peptidyl transferase center (PTC) to inhibit protein synthesis. The oxepanoprolinamide class represents a distinct type of lincosamide antibiotic that is structurally preorganized for highly effective binding to the bacterial ribosome, designed to overcome pre-existing resistance mechanisms. KV-002 is currently in the lead optimization stage, advancing toward Investigational New Drug (IND) enabling studies for the treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI), targeting all major pathogens including those resistant to known antibiotics. It is being developed for both intravenous and oral administration.